

Supplementary Content

Greater Effect of Polygenic Risk Score for Alzheimer's Disease Among Younger Cases who are Apolipoprotein E-ε4 Carriers

Brian Fulton-Howard, Alison M. Goate, Robert P. Adelson, Jeremy Koppel, Marc L. Gordon, Alzheimer's Disease Genetics Consortium, Nir Barzilai, Gil Atzmon, Peter Davies, Yun Freudenberg-Hua

Supplementary Methods

Supplementary Table 1. Characteristics of Study Participants in ADGC and LZ

Supplementary Table 2. *APOE* Genotypes of Study Participants in ADGC and LZ

Supplementary Table 3. Association Analysis of *APOE4* with AD, 89- Controls, and 90+ Controls

Supplementary Table 4. Correlation of PRS_{non-APOE} with Age

Supplementary Table 5. Interaction Between Age and *APOE4* Carrier Status on PRS_{non-APOE} in Cases and Controls

Supplementary Table 6. Sensitivity Analysis of Interaction Between Age and *APOE4* Carrier Status on PRS_{non-APOE} in Cases

Supplementary Table 7. AD Status on *APOE4* Status, Age, PRS_{non-APOE}, and Interactions using Logistic Regression

Supplementary Figure 1. Flowchart of Data Preparation and Analyses

Supplementary Figure 2. Determination of the P-Value Threshold for PRS Optimization

Supplementary Figure 3. ROC Curves for AD Risk Models

Supplementary Figure 4. Kaplan-Meier Survival Analysis using the PRS_{non-APOE} Stratified by *APOE4* Carrier Status

Ethics Statements

References for Supplementary Content

Appendix. A list of ADGC members and their affiliations.

Supplementary Methods

Additional Information on Participants

The Alzheimer's Disease Genetics Consortium (ADGC) is a multicenter consortium aiming to identify genetic risk factors for Alzheimer's disease (AD) (Naj et al., 2011). Study protocols for all cohorts were reviewed and approved by the appropriate institutional review boards. Written informed consent was obtained from participants without substantial cognitive impairment, or from authorized legal representatives for those too impaired to give consent. Enrollment criteria differed by cohort but are consistent with generally accepted clinical guidelines. Further information can be found in Kunkle et al. (Kunkle et al., 2019)

Sample and Genotype Data Quality Control

Identity by descent (IBD) was estimated using genotypes imputed to the Haplotype Reference Consortium (HRC) 1.1 reference panel (McCarthy et al., 2016) and KING (Manichaikul et al., 2010). Related individuals (proportion of identity by descent, IBD > 0.1875) within and across all cohorts were removed. PLINK 1.9 (Chang et al., 2015; Purcell et al., 2007; Shaun Purcell) was used for quality control (QC) and for ethnicity determination.

Sample-level QC and QC for genotype-level call-rate (<95%) and heterozygosity (control Hardy-Weinberg Equilibrium $P < 1 \times 10^{-6}$) were performed prior to imputation. Samples with excess or insufficient heterozygosity – greater than three standard deviations from the mean in either direction – were removed. Genotype phasing and imputation were performed using the Michigan Imputation Server (Das et al., 2016) individually for each of 37 cohorts or sub-cohorts, using all ethnicities in the HRC 1.1 reference panel. Eagle was used for phasing (Loh et al., 2016) and Minimac3 was used for imputation. Following imputation, poorly imputed ($R^2 < 0.8$) or rare (MAF < 0.01) variants were removed, and the sub-cohorts were merged for joint analysis. The data QC protocol for the Litwin Zucker Alzheimer's Research Center at the Feinstein Institutes for Medical Research (LZ) samples was previously described, utilizing several empirically-determined or consensus filters at the variant, genotype, and sample levels (Adelson et al., 2019).

After merging ADGC imputation data and LZ data, variants with low call rate (<95%) were removed, and additional samples with call rate <95% were removed. Additional QC was applied to remove variants with differential missingness between controls and cases at $P < 1 \times 10^{-4}$.

Principal Component Analysis

Principal component analysis (PCA) was performed using PLINK 1.90 (Chang et al., 2015; Shaun Purcell) on linkage disequilibrium-pruned variants with minor allele frequency $\geq 5\%$. PCA was used to remove any samples more than six standard deviations from the mean eigenvector for any of the first ten principal components (PCs), using the 1000 Genomes Project Phase 3 European superpopulation as a reference (Auton et al., 2015).

Polygenic Risk Score (PRS) Estimation

A PRS is calculated per person, i , and the number of included single nucleotide polymorphisms (SNPs, j) depends on parameters such as the GWAS significance threshold and thresholds for pruning for linkage disequilibrium (LD) (Misganaw et al., 2019).

$$PRS_i = \sum (\beta_j * SNP_{ij}).$$

We used the software PRSice-2 (Choi and O'Reilly, 2019; Euesden et al., 2015) to calculate and optimize PRS using P-value thresholding. Summary statistics from 17,008 AD cases and 37,154 controls from the International Genomics of Alzheimer's Project (IGAP) genome-wide association study (GWAS) meta-

analysis (Lambert et al., 2013) were used as base data to avoid sample overlap, since the larger AD meta-analysis from Kunkle et al. (Kunkle et al., 2019) includes the ADGC samples used in this study.

To calculate PRS without *APOE* (PRS_{non-APOE}), we excluded variants within 750 kilobases from the start or end of the *APOE* gene (chr19:44659011- 46162650, GRCh37). The summary statistics from the IGAP GWAS were linkage disequilibrium pruned at a threshold $r^2 > 0.1$ within 250-kilobase windows. *APOE* genotype (2/2, 2/3, 2/4, 3/3, 3/4, and 4/4, with one removed as the contrast), based on rs429358 and rs7412, along with eigenvectors of ten PCs and sex were included as covariates for PRS optimization.

Calculating PRS_{non-APOE} using the two control sets resulted in identical optimal P-value thresholds (P_T) for the most predictive PRS at $P_T = 1 \times 10^{-5}$. The PRS at this P_T is based on 92 SNPs associated with AD at a genome-wide significant level or suggestive level in the IGAP summary statistics (Lambert et al., 2013). This PRS model explains 1.5% of the phenotypic variation (R^2) in our cohort using either control set, based on the Nagelkerke pseudo- R^2 estimate (Nagelkerke, 1991). This PRS model was significantly associated with AD status when compared with the 90+ control-set alone ($P = 1.3 \times 10^{-6}$) as well as all ADGC controls ($P = 2.5 \times 10^{-14}$). Although both control-sets resulted in the same optimal P_T for PRS, the predictive performance of variants with weak association signals was reduced when 90+ controls were used (**Supplementary Figure 2**). To allow for comparison to previous publications, we also calculated PRS that included the *APOE* SNPs rs429358 and rs7412.

Supplementary Table 1. Characteristics of Study Participants in ADGC and LZ.

Details about AD cases and controls included in the 13 cohorts from the ADGC and the cohort from the LZ at Northwell Health. For each cohort, these details include the number of participants (*N*), the percentage of participants who are female (% female), and the mean AAO for AD cases and mean AAE for controls. For ADGC cases, age is defined as AAO as reported by the study (*n*=1,574). If AAO is not reported, we estimated AAO by subtracting ten years from age at death (AAD, *n*=102) and for those without AAD, age at last examination (AAE) is used (*n*=57). For the ADGC controls, AAE is used (*n*=2,995) and AAD is used for a small proportion of controls (*n*=126). For the LZ cohort, age is reported as age at enrollment for cases (*n*=27), and as AAE for controls (89-: *n*=35, 90+: *n*=120). The total sample utilized in this study includes 1,760 AD cases (60-99 years), 2,930 89- controls, and 346 90+ controls.

Consortium		AD cases			Controls		
		<i>N</i>	% female	Mean AAO (SD)	<i>N</i>	% female	Mean AAE (SD)
ADGC	ACT2	20	65	83.0 (6.4)	7	57.1	83.9 (6.9)
	ADC4	283	55.5	73.4 (7.0)	347	64.6	75.9 (8.2)
	ADC5	266	53.8	73.5 (6.8)	485	65.4	77.7 (9.0)
	ADC6	204	58.8	73.9 (7.7)	320	65.9	74.5 (9.0)
	ADC7	500	51.4	72.6 (7.6)	772	63.5	73.9 (7.8)
	BIOCARD	6	33.3	73.8 (6.1)	109	62.4	68.0 (5.5)
	CHAP	27	63	84.8 (7.7)	140	52.1	81.8 (6.5)
	EAS	9	44.4	85.2 (4.9)	139	41.7	84.3 (5.3)
	MTC	216	54.6	74.1 (7.4)	109	62.4	72.9 (7.2)
	NBB	50	80	76.4 (7.6)	29	55.1	81.9 (8.2)
	ROSMAP2	49	75.5	82.0 (6.8)	69	76.8	84.2 (6.4)
	WASHU2	35	57.1	72.6 (6.7)	70	50	71.5 (6.1)
	WHICAP	68	70.6	84.2 (7.9)	525	60	81.6 (6.6)
Northwell	LZ	27	37	79.2 (7.4)	155	66.5	94.7 (7.3)
Total		1760	56	74.5 (8.0)	3276	62.1	77.7 (9.4)

Abbreviations: AAD, age at death; AAE, age at last evaluation; AAO, age at onset; ACT, Adult Changes in Thought study; AD, Alzheimer's disease; ADC, NIA Alzheimer's Disease Centers cohort; ADGC, Alzheimer's Disease Genetics Consortium; BIOCARD, Biomarkers of Cognitive Decline Among Normal Individuals study; CHAP, Chicago Health and Aging Project; EAS, Einstein Aging Study; MTC, University of Miami/Texas Alzheimer's Research Care Consortium Wave 2/Case Western Reserve University cohort; LZ, Litwin Zucker Alzheimer's Research Center at the Feinstein Institutes for Medical Research; *N*, number of participants; NBB, Netherlands Brain Bank; ROSMAP, Rush University Religious Orders Study/Memory and Aging Project; SD, standard deviation; WASHU, Washington University cohort; WHICAP, Washington Heights-Inwood Columbia Aging Project.

Supplementary Table 2. APOE Genotypes of Study Participants in ADGC and LZ.

The number and percentage of *APOE4* carriers and non-carriers among AD cases, controls age 89 years or younger (89- controls), and controls age 90 years or older (90+ controls). *APOE4* non-carriers include individuals genotyped as *APOE2/2*, *APOE2/3*, and *APOE3/3*. *APOE4* carriers include individuals genotyped as *APOE2/4*, *APOE3/4*, or *APOE4/4*. *APOE2/4* carriers were excluded from the statistics for *APOE*, age and PRS interaction.

	<i>APOE4</i> non-carriers			<i>APOE4</i> carriers			Total
	2/2	2/3	3/3	2/4	3/4	4/4	
Cases (%)	2 (0.11)	85 (4.83)	654 (37.16)	60 (3.41)	753 (42.78)	206 (11.70)	1760
89- Controls (%)	8 (0.27)	328 (11.19)	1795 (61.26)	66 (2.25)	676 (23.07)	57 (1.95)	2930
90+ Controls (%)	4 (1.16)	64 (18.50)	229 (66.18)	7 (2.02)	39 (11.27)	3 (0.87)	346

Abbreviations: AD, Alzheimer's disease; *APOE2*, Apolipoprotein E-ε2 allele; *APOE3*, Apolipoprotein E-ε3 allele; *APOE4*, Apolipoprotein E-ε4 allele.

Supplementary Table 3. Association Analysis of APOE4 with AD, 89- Controls, and 90+ Controls.

Association analysis using logistic regression modeling the effect of *APOE4* allele (carriers vs. non-carrier) and the effect of E4 homozygosity (E4/E4 vs. E3/E3) with 89- controls and with 90+ controls covarying by sex and 10 PCs.

Characteristic	M1: 89- controls			M2: 90+ controls		
	Beta	95% CI	p-value	Beta	95% CI	p-value
<i>APOE4</i> carrier vs. noncarrier						
<i>APOE4</i> carrier	1.32	1.19, 1.45	3.5e-88 ***	1.96	1.62, 2.33	4.5e-27 ***
<i>APOE4/4</i> vs. 3/3						
<i>APOE4/4</i>	2.3	2.00, 2.62	9.4e-48 ***	2.87	1.87, 4.29	1.4e-06 ***

Abbreviations: AD, Alzheimer's disease; *APOE3*, Apolipoprotein E-ε3 allele; 3/3: homozygous for *APOE3*; *APOE4*, Apolipoprotein E-ε4 allele; *APOE4/4*, homozygous for *APOE4*; CI, confidence interval; PCs, principal components;

Supplementary Table 4. Correlation of PRS_{non-APOE} with Age.

M1: Without status: PRS_{non-APOE} ~ age + APOE + sex + Σ 10 PCs.

M2: With status: PRS_{non-APOE} ~ age + APOE + sex + Σ 10 PCs + case-control status.

* P<0.05, ** P<0.01, *** P<0.001.

Characteristic	M1: Without status			M2: With status		
	Beta	95% CI	P-value	Beta	95% CI	P-value
age	-7.0e-03	-0.01, -3.7e-03	2.7e-05 ***	-6.3e-03	-9.5e-03, -3.0e-03	1.6e-04 ***
APOE						
33						
34	0.04	-0.02, 0.11	0.174	-0.02	-0.08, 0.05	0.654
23	0.04	-0.05, 0.14	0.365	0.06	-0.04, 0.15	0.236
44	-0.02	-0.15, 0.11	0.729	-0.14	-0.27, -7.4e-03	0.038 *
24	0.12	-0.05, 0.29	0.178	0.07	-0.10, 0.24	0.417
22	0.01	-0.51, 0.53	0.959	0.03	-0.49, 0.55	0.902
sex	-0.01	-0.07, 0.04	0.673	2.2E-05	-0.06, 0.06	0.999
all_status						
control				-0.24	-0.30, -0.18	4.4e-14 ***

Abbreviations: APOE, Apolipoprotein E; CI, confidence interval; PCs, principal components; PRS_{non-APOE}, APOE-independent polygenic risk score.

Supplementary Table 5. Interaction Between Age and *APOE4* Carrier Status on $PRS_{non-APOE}$ in Cases and Controls.

M1: Without interactions: $PRS_{non-APOE} \sim \text{age} + APOE + \text{sex} + \sum 10 \text{ PCs}$;

M2: With interactions: $PRS_{non-APOE} \sim \text{age} * APOE + \text{sex} + \sum 10 \text{ PCs}$.

* $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$.

<i>Cases only</i>	M1: Without interactions			M2: With interactions		
Characteristic	Beta	95% CI	P-value	Beta	95% CI ¹	P-value
age	-6.90e-03	-0.01, -7.2e-04	0.029 *	1.60e-03	-7.0e-03, 0.01	0.719
E4strat						
<i>APOE4</i> carrier	-0.03	-0.13, 0.07	0.579	1.29	0.37, 2.21	6.1e-03 **
sex	-4.70e-03	-0.10, 0.09	0.922	-0.02	-0.11, 0.08	0.745
age * E4strat						
age * <i>APOE4</i> carrier				-0.02	-0.03, -5.4e-03	4.8e-03 **
<i>Controls only</i>	M1: Without interactions			M2: With interactions		
age	-5.00e-03	-8.9e-03, -1.0e-03	0.013 *	-5.10e-03	-9.5e-03, -7.6e-04	0.021 *
E4strat						
<i>APOE4</i> carrier	-0.05	-0.13, 0.04	0.267	-0.1	-0.81, 0.61	0.779
sex	-2.60e-03	-0.07, 0.07	0.943	-2.50e-03	-0.07, 0.07	0.945
age * E4strat						
age * <i>APOE4</i> carrier				7.20e-04	-8.5e-03, 9.9e-03	0.878

Abbreviations: *APOE*: Apolipoprotein E; CI: confidence interval; E4strat: *APOE4* carrier and non-carrier; PCs: principal components; $PRS_{non-APOE}$: *APOE*-independent polygenic risk score.

Supplementary Table 6. Sensitivity Analysis of Interaction Between Age and APOE4 Carrier Status on PRS_{non-APOE} in Cases.

Analysis in cases only after cases with imputed age at onset are removed.

M1: Without interactions: PRS_{non-APOE} ~ age + APOE + sex + Σ 10 PCs;

M2: With interactions: PRS_{non-APOE} ~ age * APOE + sex + Σ 10 PCs.

* P<0.05, ** P<0.01, *** P<0.001.

Cases only		M1: Without interactions			M2: With interactions		
Characteristic		Beta	95% CI	P-value	Beta	95% CI	P-value
age		-7.9e-03	-0.01, -1.2e-03	0.021 *	4.4e-04	-8.8e-03, 9.7e-03	0.926
E4strat							
	APOE4 carrier	-0.02	-0.12, 0.09	0.729	1.24	0.26, 2.23	0.013 *
sex		0.01	-0.09, 0.11	0.783	3.4e-03	-0.10, 0.10	0.946
age * E4strat							
	age * APOE4 carrier				-0.02	-0.03, -3.9e-03	0.011 *

Abbreviations: APOE4, Apolipoprotein E-ε4 allele; CI: confidence interval; E4strat, APOE4 carrier and non-carrier; PCs, principal components; PRS_{non-APOE}, APOE-independent polygenic risk score.

Supplementary Table 7. AD Status on APOE4 Status, Age, PRS_{non-APOE}, and Interactions using Logistic Regression.

M1: Without interactions: AD Status ~ age + PRS_{non-APOE} + APOE + sex + Σ 10 PCs;


M2: With interactions: AD Status ~ age * PRS_{non-APOE} * APOE + sex + Σ 10 PCs.

* P<0.05, ** P<0.01, *** P<0.001.

		M1: Without interactions			M2: With interactions		
Characteristic		Beta	95% CI	P-value	Beta	95% CI	P-value
age		-0.02	-0.03, -0.01	2.4e-06 ***	-2.5e-03	-0.01, 7.0e-03	0.603
PRS _{non-APOE}		0.23	0.17, 0.30	2.7e-12 ***	-0.30	-1.02, 0.42	0.413
E4strat							
	APOE4 carrier	1.31	1.18, 1.45	8.6e-86 ***	4.79	3.59, 6.01	8.2e-15 ***
sex		-0.26	-0.39, -0.13	6.4e-05 ***	-0.27	-0.40, -0.14	3.8e-05 ***
age * PRS _{non-APOE}					6.8e-03	-2.4e-03, 0.02	0.151
age * E4strat							
	age * APOE4 carrier				-0.05	-0.06, -0.03	1.3e-08 ***
PRS _{non-APOE} * E4strat							
	PRS _{non-APOE} * APOE4 carrier				1.31	0.10, 2.52	0.035 *
age * PRS _{non-APOE} * E4strat							
	age * PRS _{non-APOE} * APOE4 carrier				-0.02	-0.03, -1.2e-03	0.035 *


Abbreviations: APOE4, Apolipoprotein E-ε4 allele; CI, confidence interval; E4strat, APOE4 carrier and non-carrier; PCs, principal components; PRS_{non-APOE}, APOE-independent polygenic risk score.

Supplementary Figure 1. Flowchart of Data Preparation and Analyses.



Supplementary Figure 2. Determination of the P-Value Threshold for PRS Optimization


Results of clumping and thresholding. R^2 explained by PRS was calculated at IGAP GWAS P-values from 5×10^{-8} to 1. The solid line shows standard R^2 , when all ADGC controls were defined as controls, and the dotted line indicates superager R^2 , when only superagers (controls age 90 years or older) were defined as controls for PRS optimization. In both calculations, the optimal P-value threshold to maximize R^2 was 10^{-5} , which explained 1.5% of phenotypic variance.



Abbreviations: ADGC, Alzheimer's Disease Genetics Consortium; GWAS, genome-wide association study; IGAP, International Genomics of Alzheimer's Project; PRS, polygenic risk score; R^2 , variance explained.

Supplementary Figure 3. ROC Curves for AD Risk Models.


We calculated AUC for the receiver operating characteristic (ROC) curve for predicting case status with the two control groups. **(a)** ROC curves were generated for two separate models of AD risk: a standard model using all ADGC controls, and a model using only superagers (controls age 90 years or older). $PRS_{non-APOE}$ is not significantly more predictive ($P=0.067$) for 90+ controls ($AUC=0.60$) than all ADGC controls ($AUC=0.57$). The dotted line represents $AUC=0.50$. **(b)** Same models as **(a)**, except that PRS includes the $APOE4$ and $APOE2$ genotypes, 90+ controls shows significantly higher AUC (0.74 vs. 0.67 , $P=4.2 \times 10^{-6}$).



Abbreviations: AD, Alzheimer's disease; ADGC: Alzheimer's Disease Genetics Consortium; AUC, area under the curve; $PRS_{non-APOE}$, $APOE$ -independent polygenic risk score; ROC, receiver operating characteristic.

Supplementary Figure 4: Kaplan-Meier Survival Analysis using the PRS_{non-APOE} Stratified by APOE4 Carrier Status.

To visualize the effect of PRS_{non-APOE} on AAO in APOE4 carriers and non-carriers, we performed a Kaplan-Meier survival analysis, censoring controls (represented by + signs on the plot). This Kaplan-Meier curve appears to be comparable with previous publication (Desikan et al., 2017). We performed a Cox Proportional Hazards (Cox-ph) analysis of PRS quantile (Middle 80%, bottom 10% and top 10%), APOE4 carrier status, and the interaction between the two, covarying for the top two PCs and stratified by cohort. Overall, PRS quantile ($P=2.9 \times 10^{-9}$) and APOE4 carrier status ($P=9.1 \times 10^{-113}$) were highly significant in an analysis of deviance, but the interaction was nonsignificant. Compared to the middle 80% of the PRS_{non-APOE} distribution, subjects with PRS_{non-APOE} in the bottom decile have a 38% reduction in AD hazard (Cox Proportional Hazard Ratio, $HR=0.62$ and $P=1.9 \times 10^{-3}$) and those in the top decile have a 29% increased risk ($HR=1.29$ and $P=2.4 \times 10^{-2}$). APOE4 carrier status was significant in the Cox-ph model as expected ($HR=3.19$, $P=2.0 \times 10^{-94}$). The APOE effect should be interpreted cautiously because it tests as non-proportional in the "cox zph test", which would be a violation of the assumptions of the Cox-ph model.



Abbreviations: APOE4, Apolipoprotein E-ε4 allele; PRS, polygenic risk score. Bottom 10% of PRS: bottom 10% PRS_{non-APOE} distribution of all samples. Top 10% of PRS: top 10% PRS_{non-APOE} distribution of all samples.

Ethics Statements

This study conducted a secondary analysis of de-identified datasets and is not considered human subjects research according to the institutional review board (IRB) at Northwell Health. DNA samples were collected by multiple agencies with written informed consent in accordance with protocols approved by the local IRBs at Montefiore Medical Center and the Committee on Clinical Investigation at the Albert Einstein College of Medicine, Northwell Health, and participating centers of the Alzheimer's Disease Genetics Consortium (ADGC) founded by the National Institute on Aging.

References for Supplementary Content

Adelson, R.P., Renton, A.E., Li, W., Barzilai, N., Atzmon, G., Goate, A.M., Davies, P., Freudenberger-Hua, Y., 2019. Empirical design of a variant quality control pipeline for whole genome sequencing data using replicate discordance. *Sci Rep* 9(1), 16156.

Chang, C.C., Chow, C.C., Tellier, L.C., Vattikuti, S., Purcell, S.M., Lee, J.J., 2015. Second-generation PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 4, 7.

Choi, S.W., O'Reilly, P.F., 2019. PRSice-2: Polygenic Risk Score software for biobank-scale data. *Gigascience* 8(7).

Das, S., Forer, L., Schönherr, S., Sidore, C., Locke, A.E., Kwong, A., Vrieze, S.I., Chew, E.Y., Levy, S., McGue, M., Schlessinger, D., Stambolian, D., Loh, P.R., Iacono, W.G., Swaroop, A., Scott, L.J., Cucca, F., Kronenberg, F., Boehnke, M., Abecasis, G.R., Fuchsberger, C., 2016. Next-generation genotype imputation service and methods. *Nat Genet* 48(10), 1284-1287.

Euesden, J., Lewis, C.M., O'Reilly, P.F., 2015. PRSice: Polygenic Risk Score software. *Bioinformatics* 31(9), 1466-1468.

Kunkle, B.W., Grenier-Boley, B., Sims, R., Bis, J.C., Damotte, V., Naj, A.C., Boland, A., Vronskaya, M., van der Lee, S.J., Amlie-Wolf, A., Bellenguez, C., Frizatti, A., Chouraki, V., Martin, E.R., Sleegers, K., Badarinarayan, N., Jakobsdottir, J., Hamilton-Nelson, K.L., Moreno-Grau, S., Olosa, R., Raybould, R., Chen, Y., Kuzma, A.B., Hiltunen, M., Morgan, T., Ahmad, S., Vardarajan, B.N., Epelbaum, J., Hoffmann, P., Boada, M., Beecham, G.W., Garnier, J.G., Harold, D., Fitzpatrick, A.L., Valladares, O., Moutet, M.L., Gerrish, A., Smith, A.V., Qu, L., Bacq, D., Denning, N., Jian, X., Zhao, Y., Del Zompo, M., Fox, N.C., Choi, S.H., Mateo, I., Hughes, J.T., Adams, H.H., Malamon, J., Sanchez-Garcia, F., Patel, Y., Brody, J.A., Dombroski, B.A., Naranjo, M.C.D., Daniilidou, M., Eiriksdottir, G., Mukherjee, S., Wallon, D., Uphill, J., Aspelund, T., Cantwell, L.B., Garzia, F., Galimberti, D., Hofer, E., Butkiewicz, M., Fin, B., Scarpini, E., Sarnowski, C., Bush, W.S., Meslage, S., Kornhuber, J., White, C.C., Song, Y., Barber, R.C., Engelborghs, S., Sordon, S., Vojinovic, D., Adams, P.M., Vandenberghe, R., Mayhaus, M., Cupples, L.A., Albert, M.S., De Deyn, P.P., Gu, W., Himali, J.J., Beekly, D., Squassina, A., Hartmann, A.M., Orellana, A., Blacker, D., Rodriguez-Rodriguez, E., Lovestone, S., Garcia, M.E., Doody, R.S., Munoz-Fernandez, C., Sussams, R., Lin, H., Fairchild, T.J., Benito, Y.A., Holmes, C., Karamujić-Čomić, H., Frosch, M.P., Thonberg, H., Maier, W., Roshchupkin, G., Ghetti, B., Giedraitis, V., Kawalia, A., Li, S., Huebinger, R.M., Kilander, L., Moebus, S., Hernández, I., Kamboh, M.I., Brundin, R., Turton, J., Yang, Q., Katz, M.J., Concari, L., Lord, J., Beiser, A.S., Keene, C.D., Helisalmi, S., Kloszewska, I., Kukull, W.A., Koivisto, A.M., Lynch, A., Tarraga, L., Larson, E.B., Haapasalo, A., Lawlor, B., Mosley, T.H., Lipton, R.B., Solfrizzi, V., Gill, M., Longstreth, W.T., Montine, T.J., Frisardi, V., Diez-Fairen, M., Rivadeneira, F., Petersen, R.C., Deramecourt, V., Alvarez, I., Salani, F., Ciarrella, A., Boerwinkle, E., Reiman, E.M., Fievet, N., Rotter, J.I., Reisch, J.S., Hanon, O., Cupidi, C., Andre Uitterlinden, A.G., Royall, D.R., Dufouil, C., Maletta, R.G., de Rojas, I., Sano, M., Brice, A., Cecchetti, R., George-Hyslop, P.S., Ritchie, K., Tsolaki, M., Tsuang, D.W., Dubois, B., Craig, D., Wu, C.K., Soininen, H., Avramidou, D., Albin, R.L., Fratiglioni, L., Germanou, A., Apostolova, L.G., Keller, L., Koutroumani, M., Arnold, S.E., Panza, F., Gatzima, O., Asthana, S., Hannequin, D., Whitehead, P., Atwood, C.S., Caffarra, P., Hampel, H., Quintela, I., Carracedo, Á., Lannfelt, L., Rubinsztein, D.C., Barnes, L.L., Pasquier, F., Frölich, L., Barral, S., McGuinness, B., Beach, T.G., Johnston, J.A., Becker, J.T., Passmore, P., Bigio, E.H., Schott, J.M., Bird, T.D., Warren, J.D., Boeve, B.F., Lupton, M.K., Bowen, J.D., Proitsi, P., Boxer, A., Powell, J.F., Burke, J.R., Kauwe, J.S.K., Burns, J.M., Mancuso, M., Buxbaum, J.D., Bonuccelli, U., Cairns, N.J., McQuillin, A., Cao, C., Livingston, G., Carlson, C.S., Bass, N.J., Carlsson, C.M., Hardy, J., Carney, R.M., Bras, J., Carrasquillo, M.M., Guerreiro, R., Allen, M., Chui, H.C.,

Fisher, E., Masullo, C., Crocco, E.A., DeCarli, C., Bisceglia, G., Dick, M., Ma, L., Duara, R., Graff-Radford, N.R., Evans, D.A., Hodges, A., Faber, K.M., Scherer, M., Fallon, K.B., Riemenschneider, M., Fardo, D.W., Heun, R., Farlow, M.R., Kölsch, H., Ferris, S., Leber, M., Foroud, T.M., Heuser, I., Galasko, D.R., Giegling, I., Gearing, M., Hüll, M., Geschwind, D.H., Gilbert, J.R., Morris, J., Green, R.C., Mayo, K., Growdon, J.H., Feulner, T., Hamilton, R.L., Harrell, L.E., Drichel, D., Honig, L.S., Cushion, T.D., Huentelman, M.J., Hollingworth, P., Hulette, C.M., Hyman, B.T., Marshall, R., Jarvik, G.P., Meggy, A., Abner, E., Menzies, G.E., Jin, L.W., Leonenko, G., Real, L.M., Jun, G.R., Baldwin, C.T., Grozeva, D., Karydas, A., Russo, G., Kaye, J.A., Kim, R., Jessen, F., Kowall, N.W., Vellas, B., Kramer, J.H., Vardy, E., LaFerla, F.M., Jöckel, K.H., Lah, J.J., Dichgans, M., Leverenz, J.B., Mann, D., Levey, A.I., Pickering-Brown, S., Lieberman, A.P., Klopp, N., Lunetta, K.L., Wichmann, H.E., Lyketsos, C.G., Morgan, K., Marson, D.C., Brown, K., Martiniuk, F., Medway, C., Mash, D.C., Nöthen, M.M., Masliah, E., Hooper, N.M., McCormick, W.C., Daniele, A., McCurry, S.M., Bayer, A., McDavid, A.N., Gallacher, J., McKee, A.C., van den Bussche, H., Mesulam, M., Brayne, C., Miller, B.L., Riedel-Heller, S., Miller, C.A., Miller, J.W., Al-Chalabi, A., Morris, J.C., Shaw, C.E., Myers, A.J., Wiltfang, J., O'Bryant, S., Olichney, J.M., Alvarez, V., Parisi, J.E., Singleton, A.B., Paulson, H.L., Collinge, J., Perry, W.R., Mead, S., Peskind, E., Cribbs, D.H., Rossor, M., Pierce, A., Ryan, N.S., Poon, W.W., Nacmias, B., Potter, H., Sorbi, S., Quinn, J.F., Sacchinelli, E., Raj, A., Spalletta, G., Raskind, M., Caltagirone, C., Bossù, P., Orfei, M.D., Reisberg, B., Clarke, R., Reitz, C., Smith, A.D., Ringman, J.M., Warden, D., Roberson, E.D., Wilcock, G., Rogaeva, E., Bruni, A.C., Rosen, H.J., Gallo, M., Rosenberg, R.N., Ben-Shlomo, Y., Sager, M.A., Mecocci, P., Saykin, A.J., Pastor, P., Cuccaro, M.L., Vance, J.M., Schneider, J.A., Schneider, L.S., Slifer, S., Seeley, W.W., Smith, A.G., Sonnen, J.A., Spina, S., Stern, R.A., Swerdlow, R.H., Tang, M., Tanzi, R.E., Trojanowski, J.Q., Troncoso, J.C., Van Deerlin, V.M., Van Eldik, L.J., Vinters, H.V., Vonsattel, J.P., Weintraub, S., Welsh-Bohmer, K.A., Wilhelmsen, K.C., Williamson, J., Wingo, T.S., Woltjer, R.L., Wright, C.B., Yu, C.E., Yu, L., Saba, Y., Pilotto, A., Bullido, M.J., Peters, O., Crane, P.K., Bennett, D., Bosco, P., Coto, E., Boccardi, V., De Jager, P.L., Lleo, A., Warner, N., Lopez, O.L., Ingelsson, M., Deloukas, P., Cruchaga, C., Graff, C., Gwilliam, R., Fornage, M., Goate, A.M., Sanchez-Juan, P., Kehoe, P.G., Amin, N., Ertekin-Taner, N., Berr, C., Dobbie, S., Love, S., Launer, L.J., Younkin, S.G., Dartigues, J.F., Corcoran, C., Ikram, M.A., Dickson, D.W., Nicolas, G., Campion, D., Tschanz, J., Schmidt, H., Hakonarson, H., Clarimon, J., Munger, R., Schmidt, R., Farrer, L.A., Van Broeckhoven, C., C O'Donovan, M., DeStefano, A.L., Jones, L., Haines, J.L., Deleuze, J.F., Owen, M.J., Gudnason, V., Mayeux, R., Escott-Price, V., Psaty, B.M., Ramirez, A., Wang, L.S., Ruiz, A., van Duijn, C.M., Holmans, P.A., Seshadri, S., Williams, J., Amouyel, P., Schellenberg, G.D., Lambert, J.C., Pericak-Vance, M.A., Alzheimer Disease Genetics Consortium (ADGC), European Alzheimer's Disease Initiative (EADI), Cohorts for Heart and Aging Research in Genomic Epidemiology Consortium (CHARGE), Genetic and Environmental Risk in AD/Defining Genetic, P.I.a.E.R.f.A.s.D.C.G.P., 2019. Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates A β , tau, immunity and lipid processing. *Nat Genet* 51(3), 414-430.

Lambert, J.C., Ibrahim-Verbaas, C.A., Harold, D., Naj, A.C., Sims, R., Bellenguez, C., DeStefano, A.L., Bis, J.C., Beecham, G.W., Grenier-Boley, B., Russo, G., Thorton-Wells, T.A., Jones, N., Smith, A.V., Chouraki, V., Thomas, C., Ikram, M.A., Zelenika, D., Vardarajan, B.N., Kamatani, Y., Lin, C.F., Gerrish, A., Schmidt, H., Kunkle, B., Dunstan, M.L., Ruiz, A., Bihoreau, M.T., Choi, S.H., Reitz, C., Pasquier, F., Cruchaga, C., Craig, D., Amin, N., Berr, C., Lopez, O.L., De Jager, P.L., Deramecourt, V., Johnston, J.A., Evans, D., Lovestone, S., Letenneur, L., Morón, F.J., Rubinsztein, D.C., Eiriksdottir, G., Sleegers, K., Goate, A.M., Fiévet, N., Huentelman, M.W., Gill, M., Brown, K., Kamboh, M.I., Keller, L., Barberger-Gateau, P., McGuinness, B., Larson, E.B., Green, R., Myers, A.J., Dufouil, C., Todd, S., Wallon, D., Love, S., Rogaeva, E., Gallacher, J., St George-Hyslop, P., Clarimon, J., Lleo, A., Bayer, A., Tsuang, D.W., Yu, L., Tsolaki, M., Bossù, P., Spalletta, G., Proitsi, P., Collinge, J., Sorbi, S., Sanchez-Garcia, F., Fox, N.C., Hardy, J., Deniz Naranjo, M.C., Bosco, P., Clarke, R., Brayne, C., Galimberti, D., Mancuso, M., Matthews, F., Moebus, S., Mecocci, P., Del Zompo, M., Maier, W., Hampel, H., Pilotto, A., Bullido, M., Panza, F., Caffarra, P., Nacmias, B., Gilbert, J.R., Mayhaus, M., Lannefelt, L., Hakonarson, H., Pichler, S., Carrasquillo, M.M., Ingelsson, M., Beekly, D., Alvarez, V., Zou, F., Valladares, O., Younkin, S.G., Coto, E., Hamilton-Nelson, K.L., Gu, W., Razquin, C., Pastor, P., Mateo, I., Owen, M.J., Faber, K.M., Jonsson, P.V., Combarros, O., O'Donovan, M.C., Cantwell, L.B., Soininen, H., Blacker, D., Mead, S., Mosley, T.H., Bennett, D.A., Harris, T.B., Fratiglioni, L., Holmes, C., de Bruijn, R.F., Passmore, P., Montine, T.J., Bettens, K., Rotter, J.I., Brice, A., Morgan, K., Foroud, T.M., Kukull, W.A., Hannequin, D., Powell, J.F.,

Nalls, M.A., Ritchie, K., Lunetta, K.L., Kauwe, J.S., Boerwinkle, E., Riemenschneider, M., Boada, M., Hiltunen, M., Martin, E.R., Schmidt, R., Rujescu, D., Wang, L.S., Dartigues, J.F., Mayeux, R., Tzourio, C., Hofman, A., Nöthen, M.M., Graff, C., Psaty, B.M., Jones, L., Haines, J.L., Holmans, P.A., Lathrop, M., Pericak-Vance, M.A., Launer, L.J., Farrer, L.A., van Duijn, C.M., Van Broeckhoven, C., Moskvina, V., Seshadri, S., Williams, J., Schellenberg, G.D., Amouyel, P., (EADI), E.A.s.D.I., Disease, G.a.E.R.i.A.s., Consortium, A.s.D.G., Epidemiology, C.f.H.a.A.R.i.G., 2013. Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. *Nat Genet* 45(12), 1452-1458.

Loh, P.R., Danecek, P., Palamara, P.F., Fuchsberger, C., A Reshef, Y., K Finucane, H., Schoenherr, S., Forer, L., McCarthy, S., Abecasis, G.R., Durbin, R., L Price, A., 2016. Reference-based phasing using the Haplotype Reference Consortium panel. *Nat Genet* 48(11), 1443-1448.

Manichaikul, A., Mychaleckyj, J.C., Rich, S.S., Daly, K., Sale, M., Chen, W.M., 2010. Robust relationship inference in genome-wide association studies. *Bioinformatics* 26(22), 2867-2873.

McCarthy, S., Das, S., Kretschmar, W., Delaneau, O., Wood, A.R., Teumer, A., Kang, H.M., Fuchsberger, C., Danecek, P., Sharp, K., Luo, Y., Sidore, C., Kwong, A., Timpson, N., Koskinen, S., Vrieze, S., Scott, L.J., Zhang, H., Mahajan, A., Veldink, J., Peters, U., Pato, C., van Duijn, C.M., Gillies, C.E., Gandin, I., Mezzavilla, M., Gilly, A., Cocca, M., Traglia, M., Angius, A., Barrett, J.C., Boomsma, D., Branham, K., Breen, G., Brummett, C.M., Busonero, F., Campbell, H., Chan, A., Chen, S., Chew, E., Collins, F.S., Corbin, L.J., Smith, G.D., Dedoussis, G., Dorr, M., Farmaki, A.E., Ferrucci, L., Forer, L., Fraser, R.M., Gabriel, S., Levy, S., Groop, L., Harrison, T., Hattersley, A., Holmen, O.L., Hveem, K., Kretzler, M., Lee, J.C., McGue, M., Meitinger, T., Melzer, D., Min, J.L., Mohlke, K.L., Vincent, J.B., Nauck, M., Nickerson, D., Palotie, A., Pato, M., Pirastu, N., McInnis, M., Richards, J.B., Sala, C., Salomaa, V., Schlessinger, D., Schoenherr, S., Slagboom, P.E., Small, K., Spector, T., Stambolian, D., Tuke, M., Tuomilehto, J., Van den Berg, L.H., Van Rheenen, W., Volker, U., Wijmenga, C., Toniolo, D., Zeggini, E., Gasparini, P., Sampson, M.G., Wilson, J.F., Frayling, T., de Bakker, P.I., Swertz, M.A., McCarroll, S., Kooperberg, C., Dekker, A., Altshuler, D., Willer, C., Iacono, W., Ripatti, S., Soranzo, N., Walter, K., Swaroop, A., Cucca, F., Anderson, C.A., Myers, R.M., Boehnke, M., McCarthy, M.I., Durbin, R., Consortium, H.R., 2016. A reference panel of 64,976 haplotypes for genotype imputation. *Nat Genet* 48(10), 1279-1283.

Misganaw, B., Guffanti, G., Lori, A., Abu-Amara, D., Flory, J.D., Mueller, S., Yehuda, R., Jett, M., Marmar, C.R., Ressler, K.J., Doyle, F.J., SBPBC, 2019. Polygenic risk associated with post-traumatic stress disorder onset and severity. *Transl Psychiatry* 9(1), 165.

Naj, A.C., Jun, G., Beecham, G.W., Wang, L.S., Vardarajan, B.N., Bueros, J., Gallins, P.J., Buxbaum, J.D., Jarvik, G.P., Crane, P.K., Larson, E.B., Bird, T.D., Boeve, B.F., Graff-Radford, N.R., De Jager, P.L., Evans, D., Schneider, J.A., Carrasquillo, M.M., Ertekin-Taner, N., Younkin, S.G., Cruchaga, C., Kauwe, J.S., Nowotny, P., Kramer, P., Hardy, J., Huentelman, M.J., Myers, A.J., Barmada, M.M., Demirci, F.Y., Baldwin, C.T., Green, R.C., Rogaeva, E., St George-Hyslop, P., Arnold, S.E., Barber, R., Beach, T., Bigio, E.H., Bowen, J.D., Boxer, A., Burke, J.R., Cairns, N.J., Carlson, C.S., Carney, R.M., Carroll, S.L., Chui, H.C., Clark, D.G., Corneveaux, J., Cotman, C.W., Cummings, J.L., DeCarli, C., DeKosky, S.T., Diaz-Arrastia, R., Dick, M., Dickson, D.W., Ellis, W.G., Faber, K.M., Fallon, K.B., Farlow, M.R., Ferris, S., Frosch, M.P., Galasko, D.R., Ganguli, M., Gearing, M., Geschwind, D.H., Ghetti, B., Gilbert, J.R., Gilman, S., Giordani, B., Glass, J.D., Growdon, J.H., Hamilton, R.L., Harrell, L.E., Head, E., Honig, L.S., Hulette, C.M., Hyman, B.T., Jicha, G.A., Jin, L.W., Johnson, N., Karlawish, J., Karydas, A., Kaye, J.A., Kim, R., Koo, E.H., Kowall, N.W., Lah, J.J., Levey, A.I., Lieberman, A.P., Lopez, O.L., Mack, W.J., Marson, D.C., Martiniuk, F., Mash, D.C., Masliah, E., McCormick, W.C., McCurry, S.M., McDavid, A.N., McKee, A.C., Mesulam, M., Miller, B.L., Miller, C.A., Miller, J.W., Parisi, J.E., Perl, D.P., Peskind, E., Petersen, R.C., Poon, W.W., Quinn, J.F., Rajbhandary, R.A., Raskind, M., Reisberg, B., Ringman, J.M., Roberson, E.D., Rosenberg, R.N., Sano, M., Schneider, L.S., Seeley, W., Shelanski, M.L., Slifer, M.A., Smith, C.D., Sonnen, J.A., Spina, S., Stern, R.A., Tanzi, R.E., Trojanowski, J.Q., Troncoso, J.C., Van Deerlin, V.M., Vinters, H.V., Vonsattel, J.P., Weintraub, S., Welsh-Bohmer, K.A., Williamson, J., Woltjer, R.L., Cantwell, L.B., Dombroski, B.A., Beekly, D., Lunetta, K.L., Martin, E.R., Kamboh, M.I., Saykin, A.J., Reiman, E.M., Bennett, D.A., Morris, J.C., Montine, T.J., Goate, A.M., Blacker, D., Tsuang, D.W., Hakonarson, H., Kukull, W.A., Foroud, T.M., Haines, J.L., Mayeux, R., Pericak-Vance, M.A., Farrer, L.A., Schellenberg,

G.D., 2011. Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset Alzheimer's disease. *Nat Genet* 43(5), 436-441.

Purcell, S., Neale, B., Todd-Brown, K., Thomas, L., Ferreira, M.A., Bender, D., Maller, J., Sklar, P., de Bakker, P.I., Daly, M.J., Sham, P.C., 2007. PLINK: a tool set for whole-genome association and population-based linkage analyses. *Am J Hum Genet* 81(3), 559-575.

Shaun Purcell, C.C., PLINK 1.9.

Appendix

Members of the Alzheimer's Disease Genetics Consortium (ADGC)

Regina M Carney¹, Deborah C Mash², Marilyn S Albert³, Roger L Albin^{4,5}, Liana G Apostolova⁶, Steven E Arnold⁷, Michael M Barmada⁸, Lisa L Barnes^{9,10}, Thomas G Beach¹¹, Eileen H Bigio¹², Thomas D Bird¹³, Bradley F Boeve¹⁴, James D Bowen¹⁵, Adam Boxer¹⁶, James R Burk¹⁷, Nigel J Cairns¹⁸, Chuanhai Cao¹⁹, Chris S Carlson²⁰, Steven L Carroll²¹, Lori B Chibnik^{22,23}, Helena C Chui²⁴, David G Clark²⁵, Jason Corneveaux²⁶, David G Cribbs²⁷, Charles DeCarli²⁸, Steven T DeKosky²⁹, F Yesim Demirci⁸, Malcolm Dick³⁰, Dennis W Dickson³¹, Ranjan Duara³², Nilufer Ertekin-Taner^{31,33}, Kenneth B Fallon²¹, Martin R Farlow³⁴, Steven Ferris³⁵, Matthew P Frosch³⁶, Douglas R Galasko³⁷, Mary Ganguli³⁸, Marla Gearing^{39,40}, Daniel H Geschwind⁴¹, Bernardino Ghetti⁴², Sid Gilman⁴, Jonathan D Glass⁴³, John H Growdon⁴⁴, Ronald L Hamilton⁴⁵, Lindy E Harrell⁴⁶, Elizabeth Head⁴⁷, Lawrence S Honig⁴⁸, Christine M Hulette⁴⁹, Bradley T Hyman⁴⁴, Gail P Jarvik^{50,51}, Gregory A Jicha⁵², Lee-Way Jin⁵³, Anna Karydas¹⁶, John SK Kauwe⁵⁴, Jeffrey A Kaye^{55,56}, Ronald Kim⁵⁷, Edward H Koo³⁷, Neil W Kowall^{58,60}, Joel H Kramer⁶⁰, Patricia Kramer^{55,61}, Frank M LaFerla⁶², James J Lah⁴³, James B Leverenz⁶⁴, Allan I Levey⁴², Ge Li⁶⁴, Andrew P Lieberman⁶⁵, Constantine G Lyketsos⁶⁶, Wendy J Mack⁶⁷, Daniel C Marson⁴⁶, Frank Martiniuk⁶⁸, Eliezer Masliah^{37,69}, Wayne C McCormick⁷⁰, Susan M McCurry⁷¹, Andrew N McDavid²⁰, Ann C McKee^{58,59}, Marsel Mesulam⁷², Bruce L Miller¹⁶, Carol A Miller⁷³, Joshua W Miller⁷⁴, John C Morris^{18,75}, The Alzheimer's Disease Neuroimaging Initiative, Jill R Murrell^{41,76}, John M Olichney⁷⁷, Vernon S Pankratz⁷⁸, Joseph E Parisi^{79,81}, Elaine Peskind⁶⁴, Ronald C Petersen⁸¹, Aimee Pierce²⁷, Wayne W Poon²⁹, Huntington Potter⁸², Joseph F Quinn⁵⁵, Ashok Raj⁸², Murray Raskind⁶⁴, Eric M. Reiman^{26,83,84}, Barry Reisberg^{35,85}, John M Ringman⁶, Erik D Roberson⁴⁶, Howard J Rosen¹⁶, Roger N Rosenberg⁸⁶, Mary Sano⁸⁷, Andrew J Saykin^{42,88}, Julie A Schneider^{9,89}, Lon S Schneider^{6,90}, William W Seeley¹⁶, Amanda G Smith⁸², Joshua A Sonnen⁶³, Salvatore Spina⁴², Robert A Stern⁵⁸, Rudolph E Tanzi⁴⁴, John Q Trojanowski⁹¹, Juan C Troncoso⁹², Viviana M Van Deerlin⁹¹, Linda J Van Eldik⁹³, Harry V Vinters^{6,94}, Jean Paul Vonsattel⁹⁵, Sandra Weintraub⁷², Kathleen A Welsh-Bohmer^{96,97}, Jennifer Williamson⁴⁸, Randall L Woltjer⁹⁸, Chang-En Yu⁷⁰, Robert Barber⁹⁹.

1. The John P. Hussman Institute for Human Genomics, University of Miami, Miami, Florida
2. Department of Neurology, University of Miami, Miami, Florida
3. Department of Neurology, Johns Hopkins University, Baltimore, Maryland
4. Department of Neurology, University of Michigan, Ann Arbor, Michigan
5. Geriatric Research, Education and Clinical Center (GRECC), VA Ann Arbor Healthcare System (VAAHS), Ann Arbor, Michigan
6. Department of Neurology, University of California Los Angeles, Los Angeles, California
7. Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania
8. Department of Human Genetics, University of Pittsburgh, Pittsburgh, Pennsylvania
9. Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois
10. Department of Behavioral Sciences, Rush University Medical Center, Chicago, Illinois
11. Civil Laboratory for Neuropathology, Banner Sun Health Research Institute, Phoenix, Arizona
12. Department of Pathology, Northwestern University, Chicago, Illinois
13. Department of Neurology, University of Washington, Seattle, Washington
14. Department of Neurology, Mayo Clinic, Rochester, Minnesota
15. Swedish Medical Center, Seattle, Washington
16. Department of Neurology, University of California San Francisco, San Francisco, California

17. Department of Medicine, Duke University, Durham, North Carolina
18. Department of Pathology and Immunology, Washington University, St. Louis, Missouri
19. USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida
20. Fred Hutchinson Cancer Research Center, Seattle, Washington
21. Department of Pathology, University of Alabama at Birmingham, Birmingham, Alabama
22. Program in Translational NeuroPsychiatric Genomics, Institute for the Neurosciences, Department of Neurology & Psychiatry, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts
23. Program in Medical and Population Genetics, Broad Institute, Boston, Massachusetts
24. Department of Neurology, University of Southern California, Los Angeles, California
25. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama
26. Neurogenomics Division, Translational Genomics Research Institute, Phoenix, Arizona
27. Department of Neurology, University of California Irvine, Irvine, California
28. Department of Neurology, University of California Davis, Sacramento, California
29. University of Virginia School of Medicine, Charlottesville, Virginia
30. Institute for Memory Impairments and Neurological Disorders, University of California Irvine, Irvine, California
31. Department of Neuroscience, Mayo Clinic, Jacksonville, Florida
32. Wien Center for Alzheimer's Disease and Memory Disorders, Mount Sinai Medical Center, Miami Beach, Florida
33. Department of Neurology, Mayo Clinic, Jacksonville, Florida
34. Department of Neurology, Indiana University, Indianapolis, Indiana
35. Department of Psychiatry, New York University, New York, New York
36. C.S. Kubik Laboratory for Neuropathology, Massachusetts General Hospital, Charlestown, Massachusetts
37. Department of Neurosciences, University of California San Diego, La Jolla, California
38. Department of Psychiatry, University of Pittsburgh, Pittsburgh, Pennsylvania
39. Department of Pathology and Laboratory Medicine, Emory University, Atlanta, Georgia
40. Emory Alzheimer's Disease Center, Emory University, Atlanta, Georgia
41. Neurogenetics Program, University of California Los Angeles, Los Angeles, California
42. Department of Pathology and Laboratory Medicine, Indiana University, Indianapolis, Indiana
43. Department of Neurology, Emory University, Atlanta, Georgia
44. Department of Neurology, Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts
45. Department of Pathology (Neuropathology), University of Pittsburgh, Pittsburgh, Pennsylvania
46. Department of Neurology, University of Alabama at Birmingham, Birmingham, Alabama
47. Sanders-Brown Center on Aging, Department of Molecular and Biomedical Pharmacology, University of Kentucky, Lexington, Kentucky
48. Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Neurology, Columbia University, New York, New York
49. Department of Pathology, Duke University, Durham, North Carolina
50. Department of Genome Sciences, University of Washington, Seattle, Washington
51. Department of Medicine (Medical Genetics), University of Washington, Seattle, Washington
52. Sanders-Brown Center on Aging, Department Neurology, University of Kentucky, Lexington, Kentucky
53. Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California
54. Department of Biology, Brigham Young University, Provo, Utah
55. Department of Neurology, Oregon Health & Science University, Portland, Oregon
56. Department of Neurology, Portland Veterans Affairs Medical Center, Portland, Oregon
57. Department of Pathology and Laboratory Medicine, University of California Irvine, Irvine, California
58. Department of Neurology, Boston University School of Medicine, Boston, Massachusetts
59. Department of Pathology, Boston University School of Medicine, Boston, Massachusetts
60. Department of Neuropsychology, University of California San Francisco, San Francisco, California
61. Department of Molecular & Medical Genetics, Oregon Health & Science University, Portland, Oregon
62. Department of Neurobiology and Behavior, University of California Irvine, Irvine, California
63. Department of Pathology, University of Washington, Seattle, Washington

64. Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington
65. Department of Pathology, University of Michigan, Ann Arbor, Michigan
66. Department of Psychiatry, Johns Hopkins University, Baltimore, Maryland
67. Department of Preventive Medicine, University of Southern California, Los Angeles, California
68. Department of Medicine - Pulmonary, New York University, New York, New York
69. Department of Pathology, University of California San Diego, La Jolla, California
70. Department of Medicine, University of Washington, Seattle, Washington
71. School of Nursing Northwest Research Group on Aging, University of Washington, Seattle, Washington
72. Cognitive Neurology and Alzheimer's Disease Center, Northwestern University, Chicago, Illinois
73. Department of Pathology, University of Southern California, Los Angeles, California
74. Department of Pathology and Laboratory Medicine, University of California Davis, Sacramento, California
75. Department of Neurology, Washington University, St. Louis, Missouri
76. Department of Medical and Molecular Genetics, Indiana University, Indianapolis, Indiana
77. Department of Neurology, University of California Davis, Sacramento, California
78. Department of Biostatistics, Mayo Clinic, Rochester, Minnesota
79. Department of Anatomic Pathology, Mayo Clinic, Mayo Clinic, Rochester, Minnesota
80. Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota
81. Department of Neurology, Mayo Clinic, Rochester, Minnesota
82. USF Health Byrd Alzheimer's Institute, University of South Florida, Tampa, Florida
83. Arizona Alzheimer's Consortium, Department of Psychiatry, University of Arizona, Phoenix, Arizona
84. Banner Alzheimer's Institute, Phoenix, Arizona
85. Alzheimer's Disease Center, New York University, New York, New York
86. Department of Neurology, University of Texas Southwestern, Dallas, Texas
87. Department of Psychiatry, Mount Sinai School of Medicine, New York, New York
88. Department of Radiology and Imaging Sciences, Indiana University, Indianapolis, Indiana
89. Department of Pathology (Neuropathology), Rush University Medical Center, Chicago, Illinois
90. Department of Psychiatry, University of Southern California, Los Angeles, California
91. Department of Pathology and Laboratory Medicine, University of Pennsylvania, Perelman School of Medicine, Philadelphia, Pennsylvania
92. Department of Pathology, Johns Hopkins University, Baltimore, Maryland
93. Sanders-Brown Center on Aging, Department of Anatomy and Neurobiology, University of Kentucky, Lexington, Kentucky
94. Department of Pathology & Laboratory Medicine, University of California Los Angeles, Los Angeles, California
95. Taub Institute on Alzheimer's Disease and the Aging Brain, Department of Pathology, Columbia University, New York, New York
96. Department of Medicine, Duke University, Durham, North Carolina
97. Department of Psychiatry & Behavioral Sciences, Duke University, Durham, North Carolina
98. Department of Pathology, Oregon Health & Science University, Portland, Oregon
99. Department of Pharmacology and Neuroscience, University of North Texas Health Science Center, Fort Worth, Texas